We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Advaxis announced that its GMP clinical materials have passed quality control release and are available for use in a Phase I/II clinical trial of Lovaxin C in advance cervical cancer patients.
Australian cancer drug development company Progen Industries has announced the expansion of the Phase II clinical trial program of its lead anti-cancer product, PI-88, into prostate cancer.
Rigel Pharmaceuticals has enrolled the first patient in a comparative Phase II clinical study of R112, a potential intranasal therapy for the treatment of allergic rhinitis.
Actelion has announced the preliminary result of a double-blind, placebo-controlled, randomized, multicenter, 190-patient Phase III study, RAPIDS-2, with the dual endothelin receptor antagonist bosentan (Tracleer) in systemic sclerosis patients suffering from digital ulceration.
Alexion Pharmaceuticals and Procter & Gamble have announced the completion of enrollment for the pivotal Phase III PRIMO-CABG2 efficacy trial of pexelizumab.
Intercell announced that it has received the approval for the start of Phase III clinical studies for the Japanese Encephalitis Vaccine (IC51) from major European authorities.
Pozen has announced the submission of a new drug application (NDA) to the FDA for the marketing approval of Trexima, the proposed brand name for the combination of sumatriptan succinate and naproxen sodium, in a single tablet for the acute treatment of migraine.